Pernix Theraptcs Cmn (PTX) 0.64 $PTX Pernix Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pernix Theraptcs Cmn (PTX) 0.64 $PTX

Pernix Therapeutics Reports Second Quarter 2016 Financial Results and Business Update
GlobeNewswire - Thu Aug 11, 3:01PM CDT
Net Revenue Increased 13% Sequentially Over First Quarter 2016
PTX: 0.64 (+0.04)

Pernix Therapeutics to Report Second Quarter 2016 Financial Results on August 11, 2016
GlobeNewswire - Thu Aug 04, 5:31AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the second quarter ended June 30, 2016, after the market close on Thursday, August 11, 2016. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
PTX: 0.64 (+0.04)

Research Report on These Healthcare Sector Equities -- Valeant Pharma, Pernix Therapeutics, Perrigo, and Lipocine
PR Newswire - Mon Aug 01, 6:35AM CDT
The number of individuals who require medical attention and treatment is constantly growing, which is why Healthcare stocks remain in high demand. Earnings growth potential within the healthcare sector is much higher compared with other sectors, opening long-term opportunities for investors. Stock-Callers.com reviews the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Perrigo Co. PLC (NYSE: PRGO), and Lipocine Inc. (NASDAQ: LPCN). Learn more about these stocks by accessing their free research reports at:
PRGO: 90.99 (-0.03), VRX: 29.03 (-1.22), PTX: 0.64 (+0.04), LPCN: 3.37 (-0.17), VRX.TO: 38.09 (-1.51)

Pernix Therapeutics Announces Positive Phase IV Results of Silenor(R) vs. Zolpidem Head-to-Head Arousability Study
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Data demonstrated that Pernix Therapeutics' Silenor 6 mg was superior to zolpidem 10 mg on all measures evaluated.
PTX: 0.64 (+0.04)

Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro(R) ER with BeadTek(TM)
GlobeNewswire - Wed May 25, 7:08AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark Office has issued U.S. Patent Numbers 9,339,499 ('499 patent), 9,326,982 ('982 patent), and 9,333,201 ('201 patent), covering important safety information related to dosing patients with Zohydro ER with BeadTek. These patents, in addition to the 9,265,760 patent ('760 patent) which issued February 23, 2016, are broadly directed to a method of dosing patients with hepatic impairment with hydrocodone where no adjustment in start dose is needed for patients with mild or moderate hepatic impairment. The '760, '499, '982 and '201 patents expire July 25, 2033.
PTX: 0.64 (+0.04)

Pernix Therapeutics Announces CEO Transition
GlobeNewswire - Wed May 11, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced that Doug Drysdale, after discussions with the Company's Board of Directors, has agreed to step down as Chairman of the Board, Chief Executive Officer and President, and has resigned as a member of the Board of Directors, effective May 9, 2016. John Sedor, a current Director of Pernix Therapeutics, has been appointed Chairman of the Board and Interim Chief Executive Officer of the Company while the Board of Directors searches for a permanent CEO. The Board currently intends that Mr. Sedor will remain as Chairman of the Board when a new CEO is appointed.
PTX: 0.64 (+0.04)

Pernix Therapeutics Overcomes Challenge to Treximet(R) '183 Patent
GlobeNewswire - Mon May 09, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced that on May 6, 2016, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied a petition for inter partes review (IPR) filed by Graybar Pharmaceuticals, LLC (now Gray Square Pharmaceuticals, LLC) against Pozen, Inc. This petition, which was filed on November 12, 2015, sought review of certain claims of U.S. Patent No. 7,332,183 ('183 patent), which expires 2026. The '183 patent is licensed by Pernix and is one of several FDA Orange Book listed patents covering Treximet(R), manufactured and sold by Pernix Therapeutics, (sumatriptan/naproxen sodium), a prescription medication for acute migraine attacks, with or without aura.
PTX: 0.64 (+0.04), POZN: 5.94 (-0.43)

Pernix Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 8:19AM CDT
MORRISTOWN, N.J. (AP) _ Pernix Therapeutics Holdings Inc. (PTX) on Thursday reported a loss of $25.9 million in its first quarter.
PTX: 0.64 (+0.04)

Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
GlobeNewswire - Thu May 05, 7:01AM CDT
Pernix Prescriptions Direct Achieves Increased Penetration
PTX: 0.64 (+0.04)

Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016
GlobeNewswire - Thu Apr 28, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, announced today that it will release financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016. Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host a conference call to discuss the results, as follows.
PTX: 0.64 (+0.04)

Pernix Therapeutics to Present at Needham & Company's 15th Annual Healthcare Conference
GlobeNewswire - Tue Apr 05, 3:01PM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at Needham & Company's 15th Annual Healthcare Conference, as follows.
PTX: 0.64 (+0.04)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launch Investigation of Pernix Therapeutics Holdings, Inc. for Possible Breaches of Fiduciary Duty
PR Newswire - Thu Jan 14, 11:15AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) in connection with possible breaches of fiduciary duty.
PTX: 0.64 (+0.04)

Zogenix, Inc Gained 29% in 2015 -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jan 14, 10:59AM CST
What:  2015 was a great year to be a Zogenix shareholder. The clinical-stage biopharmaceutical company's stock soared more than 29% higher during the year, according to data from S&P Capital IQ . So what: The year was filled with...
PTX: 0.64 (+0.04), ZGNX: 8.72 (-0.61)

The Zacks Analyst Blog Highlights: Amphastar Pharmaceuticals, Mylan, Pernix Therapeutics Holdings, Eli Lilly and Novo Nordisk
Zacks Equity Research - Zacks Investment Research - Wed Nov 25, 8:30AM CST
The Zacks Analyst Blog Highlights: Amphastar Pharmaceuticals, Mylan, Pernix Therapeutics Holdings, Eli Lilly and Novo Nordisk
NVO: 46.72 (-0.41), PTX: 0.64 (+0.04), MYL: 42.36 (-0.39), LLY: 77.75 (-0.02), AMPH: 19.00 (-0.45)

Forget Allergan & Pfizer, Buy These Drug Stocks Instead
Arpita Dutt - Zacks Investment Research - Tue Nov 24, 11:09AM CST
Let's take a look at some drug stocks with an attractive Zacks Rank and positive estimate revisions.
AGN: 234.54 (-2.45), NVO: 46.72 (-0.41), PTX: 0.64 (+0.04), PFE: 34.80 (-0.08), MYL: 42.36 (-0.39), LLY: 77.75 (-0.02), AMPH: 19.00 (-0.45)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Pernix Therapeutics Holdings, Inc. - PTX
ACCESSWIRE - Mon Nov 16, 3:30PM CST
NEW YORK, NY / ACCESSWIRE / November 16, 2015 / Levi & Korsinsky announces it has commenced an investigation of Pernix Therapeutics Holdings, Inc. (NasdaqGM: PTX) concerning possible breaches of fiduciary duty by its Board of Directors. To obtain additional information, GO TO:
PTX: 0.64 (+0.04)

Pernix Therapeutics to Present at Stifel 2015 Healthcare Conference
GlobeNewswire - Fri Nov 13, 6:00AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the Stifel 2015 Healthcare Conference as follows:
PTX: 0.64 (+0.04)

Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From a Phase IV Study to Assess and Compare the Effects of Silenor 6 mg and zolpidem 10 mg on Balance, Cognitive Performance, and Arousability
GlobeNewswire - Thu Nov 12, 10:15AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV Study assessing the effects of a nighttime administration of Silenor 6 mg, zolpidem 10 mg, and placebo on arousability, gait/balance, and cognitive performance in healthy volunteers. The study assessed the effects of a single dose of Silenor 6 mg compared with matching placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the respective Tmax (amount of drug present at the maximum serum concentration) in normal healthy adult male volunteers (n=39). The interim results of this head-to-head comparison demonstrate that Silenor 6 mg is statistically significantly superior to zolpidem 10 mg on all measures analyzed. The results also indicate that subjects taking Silenor 6 mg did not have impairment on any of these measures and were comparable to placebo. Further, Silenor 6 mg and both placebo groups were superior to zolpidem on all measures, indicating that zolpidem subjects had significant difficulty waking up, difficulty in their ability to walk, difficulty with balance, and experienced memory impairment.
PTX: 0.64 (+0.04)

Pernix Therapeutics to Host Meetings at Upcoming Conferences
GlobeNewswire - Tue Nov 10, 3:30PM CST
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host investor meetings at two upcoming conferences:
PTX: 0.64 (+0.04)

The Zacks Analyst Blog Highlights: Teva Pharmaceutical Industries, Mylan, Impax Laboratories, Teligent and Pernix Therapeutics Holdings
Zacks Equity Research - Zacks Investment Research - Fri Nov 06, 8:30AM CST
The Zacks Analyst Blog Highlights: Teva Pharmaceutical Industries, Mylan, Impax Laboratories, Teligent and Pernix Therapeutics Holdings
IPXL: 24.19 (-0.23), PTX: 0.64 (+0.04), MYL: 42.36 (-0.39), TEVA: 50.39 (-0.17), TLGT: 7.42 (-0.21)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 234

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 143

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 45

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 116

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 98

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 35

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 10

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 80

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading

Top 5 Most Recently Viewed Articles

U.S. Industrial Production Unexpectedly Declines, Impacting Growth

Updated Category News Views 62

U.S. Industrial Production Experiences a Notable Decline The latest report reveals that U.S. industrial production has faced an unexpected decline, recorded at -0.3%. This drop highlights the ongoing struggles within the manufacturing, mining, and utility sectors. Disappointing Performance Against Expectations When comparing the -0.3% figure to a predicted decrease of...

Continue Reading
MAXHUB Partners with Microsoft to Enhance Teams Rooms Experience

Updated Category News Views 363

MAXHUB Collaborates with Microsoft to Enhance Teams In an exciting development within the tech landscape, MAXHUB is teaming up with Microsoft in an initiative aimed at improving the security and reliability of Microsoft Teams Rooms. This partnership aligns with MAXHUB's vision of leading in integrated commercial display and unified communications solutions, providing...

Continue Reading
US Dollar Strengthens While Global Markets Face Turmoil

Updated Category News Views 486

US Dollar's Rise Amid Trade Tensions In an unexpected turn of events, the US dollar has extended its gains following President Trump's announcement of new tariffs. As the global markets react to these developments, we dive into the implications for various economies and asset classes. The latest updates indicate that the 25% tariffs on imports from Canada and Mexico,...

Continue Reading
Understanding Your Rights as a Perrigo Company Shareholder

Updated Category News Views 135

Understanding Your Rights as a Perrigo Company Shareholder Shareholders of Perrigo Company plc (NYSE: PRGO) should stay informed about recent developments regarding potential securities law violations. The underlying issues stem from allegations that the company misled investors regarding its infant formula business, which has drawn significant scrutiny. Allegations...

Continue Reading
Spring Surprises: White Castle Unveils Exciting Deals Ahead

Updated Category News Views 521

Spring Promotions at White Castle As the season transforms, White Castle, the pioneering fast-food restaurant known for its Original Slider, unveils enticing deals for its loyal customers. Embracing longer days and warmer weather, the company is determined to deliver exceptional savings for all cravings this spring. Celebrating with Value-Driven Offers White Castle is...

Continue Reading